Molecular formula: C181H291N55O51S2
Molecular weight: 4117. 77 g·mol−1
Patent period: —
Dositive specifications: –
Injection : –
Oral tablets: —
Injection: —
Molecular formula: C181H291N55O51S2
Molecular weight: 4117. 77 g·mol−1
Patent period: —
Dositive specifications: –
Injection : –
Oral tablets: —
Injection: —
Teriparatide is indicated for the treatment of postmenopausal women with osteoporosis; for the increase of bone mass in men with primary or hypogonadal osteoporosis; and treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.
| CAS NO. | 52232-67-4 |
|---|---|
| FORMULA | C181H291N55O51S2 |
| M. WT | 4117. 77 g·mol−1 |
| Bioavailability | 95% |
| Metabolism | Liver (nonspecific proteolysis) |
| STORAGE | — |